Stock AnalizQuest Diagnostics Inc. DGX
Medical Specialities · data as of November 13, 2026
Quest Diagnostics Inc. (DGX) is a healthcare company listed in the US with a market value of about $28.6B. In the twelve months to September 30, 2026 it had revenue of $11.8B and net income of $1.1B, a net margin of 9.5%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is shareholder returns (5/5); the weakest is value (0/5).
Key numbers: a P/E of 25.9, a price to free cash flow of 20.8, 5-year revenue growth of 3% a year, a 5-year average ROIC of 10%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 7% below the current price.
Score: 2.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profitable 5 years in a row
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Pays a dividend
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.8B | $11.0B | $9.9B | $9.3B | $9.9B | $10.8B | $9.4B | $7.7B | $7.5B | $7.4B | $7.2B |
| Net income | $1.1B | $992M | $871M | $854M | $946M | $2.0B | $1.4B | $858M | $736M | $772M | $645M |
| Free cash flow | $1.4B | $1.4B | $909M | $864M | $1.3B | $1.8B | $1.6B | $843M | $817M | $923M | $823M |
| EPS (diluted) | $10.04 | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 |
| Net margin | 9.5% | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.4% | 8.9% |
| ROIC | — | 8.8% | 7.5% | 8.4% | 10.7% | 16.5% | 13.1% | 8.6% | 9.2% | 10.2% | 9.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $257.27, 1% below the current price; targets range from $235.00 to $279.00; the consensus rating is “Buy”; expected EPS is $11.32 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Quest Diagnostics’s P/E ratio?
About 25.9, based on the last twelve months of diluted earnings per share (forward P/E about 22.8).
Is Quest Diagnostics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 7% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Quest Diagnostics pay a dividend?
Yes. The dividend yield is about 1.33%, and it has paid dividends for 10 years in our data.
Is Quest Diagnostics a good stock to buy?
We do not give buy or sell advice. Quest Diagnostics scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.